--- title: "Tiziana Life Sciences Highlights Preclinical Long COVID Brain Fog Data for Intranasal Foralumab" type: "News" locale: "en" url: "https://longbridge.com/en/news/282992227.md" description: "Tiziana Life Sciences (TLSA) announced positive preclinical data on April 16, 2026, showing that intranasal anti-CD3 antibody treatment reduced neuroinflammation and improved cognition in a mouse model of Long COVID. The study, led by Yale University and Brigham and Women’s Hospital, indicated increased regulatory T cells and restoration of neurogenesis, supporting Tiziana's intranasal foralumab programs. Analysts rate TLSA stock as a Buy with an $8.00 price target. Tiziana focuses on immunotherapy for neuroinflammatory diseases, with a current market cap of $158.1M." datetime: "2026-04-16T11:34:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282992227.md) - [en](https://longbridge.com/en/news/282992227.md) - [zh-HK](https://longbridge.com/zh-HK/news/282992227.md) --- # Tiziana Life Sciences Highlights Preclinical Long COVID Brain Fog Data for Intranasal Foralumab ### Claim 30% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest announcement is out from Tiziana Life Sciences ( (TLSA) ). On April 16, 2026, Tiziana Life Sciences reported positive preclinical data from independent academic collaborators showing that intranasal anti-CD3 antibody treatment reduced neuroinflammation and improved cognition in a mouse model of Long COVID. The bioRxiv study, which evaluated a nasal anti-CD3 monoclonal antibody resembling Tiziana’s foralumab, also found increased regulatory T cells in the brain, restored hippocampal neurogenesis and reversal of “brain fog”-like deficits, reinforcing the rationale for Tiziana’s intranasal foralumab programs and potentially bolstering its positioning in post-viral neuroinflammatory indications. The work, led by researchers at Yale University and Brigham and Women’s Hospital, used a mild respiratory SARS-CoV-2 mouse model and complementary human data showing reduced circulating Tregs in Long COVID patients with neurological symptoms. Executives said the findings validate the mechanistic foundation for ongoing clinical efforts in multiple sclerosis and other neurodegenerative diseases, and may support expansion into Long COVID “brain fog,” adding momentum to Tiziana’s broader intranasal immunotherapy platform. The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page. **More about Tiziana Life Sciences** Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on immunotherapy delivered through alternative routes, particularly intranasal administration. Its lead asset, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, targets neuroinflammatory and neurodegenerative diseases, including non-active secondary progressive multiple sclerosis, MSA, Alzheimer’s disease and ALS. **Average Trading Volume:** 174,625 **Technical Sentiment Signal:** Hold **Current Market Cap:** $158.1M For an in-depth examination of TLSA stock, go to TipRanks’ Overview page. ### Related Stocks - [TLSA.US](https://longbridge.com/en/quote/TLSA.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) ## Related News & Research - [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md) - [Artiva says AB-101 plus rituximab posts 71% ACR50 response in refractory RA study](https://longbridge.com/en/news/286959967.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)